Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AspECT: Aspirin and esomeprazole chemoprevention in Barrett's metaplasia and oesophagitis
2004-003836-77Phase 3Completed
- Sponsor
- University of Oxford
- Start
- Apr 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of aspirin and esomeprazole in Barrett's esophagus, esophagitis, esophageal adenocarcinoma (EAC) and 1 more, sponsored by University of Oxford. Primary endpoints: All-cause mortality and Progression to oesophageal adenocarcinoma or high-grade dysplasia. Started Apr 2008; status: completed.
02
Drugs
aspirinesomeprazole
03
Conditions
Barrett's esophagusesophagitisesophageal adenocarcinoma (EAC)Esophageal high-grade dysplasia (HGD)
Beyond the preview
Go deeper on 2004-003836-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003836-77.